Nature Communications (Oct 2024)

Annonaceous acetogenins mimic AA005 targets mitochondrial trifunctional enzyme alpha subunit to treat obesity in male mice

  • Bing Han,
  • Zhan-Ming Li,
  • Xu-Yun Zhao,
  • Kai Liang,
  • Yu-Qin Mao,
  • Shi-Long Zhang,
  • Li-Ying Huang,
  • Chao-Yue Kong,
  • Xin Peng,
  • Hui-Ling Chen,
  • Jia-Ting Huang,
  • Zhao-Xia Wu,
  • Jin-Qing Yao,
  • Pei-Ran Cai,
  • Zheng-Yan Zhang,
  • Xu-Min Zhang,
  • Zhu-Jun Yao,
  • Guo-Qiang Chen,
  • Li-Shun Wang

DOI
https://doi.org/10.1038/s41467-024-53118-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Obesity and related diseases pose a major health risk, yet current anti-obesity drugs inadequately addressing clinical needs. Here we show AA005, an annonaceous acetogenin mimic, resists obesity induced by high-fat diets and leptin mutations at non-toxic doses, with the alpha subunit of the mitochondrial trifunctional protein (HADHA) as a target identified through proteomics and in vitro validation. Pharmacokinetic analysis shows AA005 enriches in adipose tissue, prompting the creation of adipose-specific Hadha-deficient mice. These mice significantly mitigate diet-induced obesity, echoing AA005’s anti-obesity effects. AA005 treatment and Hadha deletion in adipose tissues increase body temperature and energy expenditure in high-fat diet-fed mice. The beneficial impact of AA005 on obesity mitigation is ineffective without uncoupling protein 1 (UCP1), essential for thermogenesis regulation. Our investigation shows the interaction between AA005 and HADHA in mitochondria, activating the UCP1-mediated thermogenic pathway. This substantiates AA005 as a promising compound for obesity treatment, targeting HADHA specifically.